Tag: Biotech and Pharma

Novo Nordisk and Eli Lilly rival soars 32% after promising weight-loss drug results

Shares of Denmark’s Zealand Pharma shot 32% higher in morning trade, after results showed success in its liver disease treatment survodutide, which is also on trial as a drug to treat obesity.

Moderna posts surprise quarterly profit even as Covid vaccines sales plummet

Moderna posted a surprise quarterly profit, in part boosted by deferred revenue, even as the company saw slumping sales from its Covid vaccine, its only marketable product. 

Lavipharm: Γιατί σήμερα μπαίνουν οι βάσεις για απογείωση του EBITDA

Ιστορική μέρα η σημερινή για την Lavipharm, καθώς 1,5 χρόνο μετά την αύξηση κεφαλαίου που άλλαξε τον ρου της εισηγμένης στη χρηματιστηριακή θάλασσα, γίνεται πράξη η είσοδό της στην φαρμακευτική κάνναβη και όλα δείχνουν πως πραγματώνεται ο στόχος για εκτίναξη των EBITDA ως το 2025.

Lavipharm: Δύο αλλαγές με όφελος 350 χιλ. ευρώ

Τη διακοπή της δραστηριότητας φαρμακαποθήκης και υπηρεσιών logistics προς τρίτους ανακοίνωσε η Lavipharm, καθώς και τη μεταβίβαση ορισμένων στοιχείων του ενεργητικού της θυγατρικής της εταιρείας LAS στην Profarm.

Kenvue’s stock slides 2.6% as J & J spinoff’s revenue and guidance fall short of expectations

Kenvue Inc.’s stock fell 2.6% early Thursday, after the consumer-health business spun out from Johnson & Johnson last year missed revenue estimates for the fourth quarter and offered soft guidance for 2024.

AstraZeneca Shares Drop After Weak Quarterly Print Despite 2024 Growth Guidance — 2nd Update

AstraZeneca sees its revenue and core earnings per share growing by double-digit percentages in 2024, the pharmaceuticals major said as it reported fourth-quarter core earnings per share below expectations on higher costs, sending the stock lower.

Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue

Eli Lilly reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes treatment, Mounjaro.

Novo Nordisk parent to buy Catalent for $11.5 bln to boost Wegovy supply

Novo Holdings, parent of Novo Nordisk (NOVOb.CO), opens new tab, will buy contract drugmaker Catalent (CTLT.N), opens new tab for $11.5 billion in cash to help meet the strong demand for its popular weight-loss drug Wegovy, the companies said on Monday.

Merck results beat expectations as top drugs Keytruda, Gardasil post strong sales

Merck reported fourth-quarter revenue and adjusted earnings that topped estimates as it saw strong demand for its blockbuster cancer drug Keytruda and HPV vaccine Gardasil.

Novo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, Ozempic

The maker of weight loss drug Wegovy and diabetes drug Ozempic reported an increase in sales of 31% in Danish kroner and 36% at constant exchange rates to 232.3 billion kroner ($33.71 billion).

Pfizer beats earnings estimates as declining Covid business loses less revenue than expected

Pfizer posted a surprise adjusted fourth-quarter profit, as the company’s declining Covid business performed better than expected.

Bayer shares fall nearly 6% on court order to pay $2.25 bln in damages

Shares in Bayer dropped as much as 5.7% on Monday after the embattled German company was ordered to pay $2.25 billion in damages, the highest amount yet in its ongoing litigation linked to an alleged carcinogenic effect of its Roundup weedkiller.

Συνεργασία Famar-Lavipharm στην παραγωγή φαρμάκων

Στο πλαίσιο της συμφωνίας, η FAMAR θα αναλάβει, ως αποκλειστικός πάροχος, την παραγωγή των αναλγητικών φαρμακευτικών προϊόντων Lonarid N® και Lonalgal® της Lavipharm.

Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump

Johnson & Johnson reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations.

J&J to buy targeted cancer therapy developer Ambrx for $2 bln

Johnson & Johnson said on Monday it had agreed to buy drug developer Ambrx Biopharma  for $2 billion to gain access to drugs that belong to a class of targeted cancer therapies which have drawn interest from other drugmakers.

Lilly launches website, home delivery option for weight-loss drugs

Eli Lilly and Co on Thursday launched a website to help people with obesity get prescriptions through telehealth providers and provide home delivery of its weight-loss medicines.

Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion

Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash.

Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 billion

 Bristol Myers Squibb  on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising experimental schizophrenia drug to help power growth as patents on its older therapies expire later this decade.

Moderna Reports More Promising Data on Its Cancer Treatment

Moderna on Thursday unveiled new data from a continuing early-stage trial of the personalized cancer treatment it is testing with Merck, saying that the updated results help build the case that the drug works.

Pfizer shares sink after weak 2024 forecasts

Dec 13 (Reuters) – Pfizer on Wednesday forecast 2024 revenue and profit below Wall Street expectations, sending its shares down 7% in premarket trading even as it raised cost-cut target by $500 million.